GLP-1 Use Quadruples; Interval Exercise; Endometriosis Link

Americans' use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll. The poll surveyed 10,000 individuals and found that 15% of respondents reported using GLP-1 receptor agonists for weight management. This represents a significant increase from 2024, when only 4% reported such use.

The use of these medications is particularly prevalent among individuals aged 30-50, with 22% in this demographic reporting current use. For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists have shown benefits beyond glycemic control, including improved cardiovascular outcomes. A meta-analysis published in the Journal of the American Medical Association in October 2024 indicated a 25% reduction in major adverse cardiovascular events for patients with established cardiovascular disease on GLP-1 therapy.

Separately, research presented at the American College of Sports Medicine's annual meeting this week highlighted the benefits of intense interval exercise. Studies involving 500 participants demonstrated that high-intensity interval training (HIIT) for 20 minutes, three times a week, resulted in a 30% greater improvement in VO2 max compared to moderate-intensity continuous training over a 12-week period. This type of exercise is recommended for improving cardiovascular fitness and metabolic health.

Furthermore, new findings published in the journal "Endocrinology" on November 15, 2024, suggest a potential link between elevated androgen levels and the severity of endometriosis. The study, which analyzed blood samples from 800 women, found that women with higher circulating levels of testosterone and dehydroepiandrosterone sulfate (DHEA-S) were more likely to have advanced stages of endometriosis, characterized by deeper lesions and greater pelvic pain. Researchers are exploring whether androgen-blocking therapies could offer new treatment avenues for severe endometriosis.